Sanofi-Aventis: Eloxatin-based regimens extend survival beyond two years in colorectal cancer

By Elaine Rigoli

Tampa, Fla., June 6 - Sanofi-Aventis announced key results from three studies evaluating Eloxatin (oxaliplatin injection) in various gastrointestinal tumor types - colorectal, pancreatic and gastric cancers.

The company said final analysis demonstrates that Eloxatin-based chemotherapy combined with bevacizumab provided significant improvement in overall survival for patients with advanced colorectal cancer.

Results from this study evaluating the use of Eloxatin-based regimens plus bevacizumab demonstrate a greater than two-year median overall survival among patients with metastatic colorectal cancer, the longest survival results seen to date in this patient population, according to a news release.

Sanofi-Aventis is a Paris-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.